CASI Pharmeceuticals

View All
Casi Pharmaceuticals

CASI Pharmaceuticals CEO Ken K. Ren, PhD rang the closing bell at NASDAQ on Thursday, June 11, 2015 4PM.

About Us

CASI Pharmaceuticals (NASDAQ: CASI), is a U.S. biopharmaceutical company dedicated to rapidly bringing high quality pharmaceutical products and innovative oncology therapeutics to patients. Our integrated China/U.S. drug development strategy is cost-effective and can accelerate product registration. Our business mission is to become an integrated pharmaceutical company with significant market presence in greater China, while establishing strategic partnerships for development and commercialization outside of China. Our patient-focused mission is to maximize patient access to high quality and innovative therapeutics in order to better patient lives and address significant unmet medical needs.

Learn More

Presentation

Corporate Presentation - H.C. Wainwright Global Life Sciences Conference

Download →

Presentation

Clinical Safety and Efficacy of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated, Locally Advanced or Metastatic Triple-Negative Breast Cancer

Download →

Presentation

Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret Phase 2 consortium

Download →

Receive press releases via email